Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The <scp>CANPIONE</scp> study-Reference-Cited by-同舟云学术

Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study

Published:2022-05-18 Issue:8 Volume:24 Page:1429-1438
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Miyamoto Satoshi¹^ORCID,Heerspink Hiddo J. L.²^ORCID,de Zeeuw Dick²,Toyoda Masao³,Suzuki Daisuke⁴,Hatanaka Takashi⁵,Nakamura Tohru⁶,Kamei Shinji⁷,Murao Satoshi⁸,Hida Kazuyuki⁹,Ando Shinichiro¹⁰,Akai Hiroaki¹¹,Takahashi Yasushi¹²,Koya Daisuke¹³¹⁴¹⁵,Kitada Munehiro¹³¹⁴^ORCID,Sugano Hisashi¹⁶,Nunoue Tomokazu¹⁷,Nakamura Akihiko¹⁸,Sasaki Motofumi¹⁹,Nakatou Tatsuaki²⁰,Fujimoto Kei²¹,Kawanami Daiji²²,Wada Takashi²³,Miyatake Nobuyuki²⁴,Yoshida Michihiro¹,Shikata Kenichi¹,

Affiliation:

1. Center for Innovative Clinical Medicine Okayama University Hospital Okayama Japan

2. Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen Groningen the Netherlands

3. Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine Tokai University School of Medicine Isehara Japan

4. Suzuki Diadetes Clinic Atsugi Japan

5. Department of Diabetes and Endocrinology National Hospital Organization Fukuyama Medical Center Fukuyama Japan

6. Diabetes Internal Medicine Sumitomo Besshi Hospital Nihama Japan

7. Department of Diabetic Medicine Kurashiki Central Hospital Kurashiki Japan

8. Department of Diabetes and Endocrinology Takamatsu Hospital Takamatsu Japan

9. Department of Diabetology and Metabolism National Hospital Organization Okayama Medical Center Okayama Japan

10. Department of Internal Medicine Diabetic Center Okayama City Hospital Okayama Japan

11. Division of Diabetes and Metabolism, Faculty of Medicine Tohoku Medical and Pharmaceutical University Sendai Japan

12. Department of Diabetes Ochiai General Hospital Maniwa Japan

13. Department of Diabetology and Endocrinology Kanazawa Medical University Uchinada Japan

14. Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute Kanazawa Medical University Uchinada Japan

15. Omi Medical Center Kusatsu Japan

16. Department of Diabetes and Endocrinology Kochi Health Sciences Center Kochi Japan

17. Nunoue Clinic Tsuyama Japan

18. Internal Medicine, Osafune Clinic Setouchi Japan

19. Department of Diabetes and Endocrinology Matsue City Hospital Matsue Japan

20. Diabetes Center Okayama Saiseikai General Hospital Okayama Japan

21. Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine The Jikei University Kashiwa Hospital Kashiwa Japan

22. Department of Endocrinology and Diabetes Mellitus Fukuoka University School of Medicine Fukuoka Japan

23. Department of Nephrology and Laboratory Medicine, Graduate School of Medical Sciences Kanazawa University Kanazawa Japan

24. Department of Hygiene, Faculty of Medicine Kagawa University Miki Kagawa Japan

Funder

Mitsubishi Tanabe Pharma Corporation

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14731

Reference34 articles.

1. World Health Organization.Global report on diabetes.https://www.who.int/publications/i/item/9789241565257. Accessed January 21 2022.

2. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)

3. Nephron Protection in Diabetic Kidney Disease

4. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

5. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope;Kidney International;2024-08